Researchers at CUNY create guidelines for morphable nanomaterials to diagnose, target and effectively treat Life-Threatening Illness such as Cancer, Cardiovascular and Autoimmune diseases

Peptides spontaneously form spherical or worm-like nanostructures that can be morphed or broken down by enzymes overexpressed in cancer cells. By controlling the shape and charge of the nanostructures, scientists can predict the rate of …more

Scientists have long sought to develop drug therapies that can more precisely diagnose, target and effectively treat life-threatening illness such as cancer, cardiovascular and autoimmune diseases.

One promising approach is the design of morphable nanomaterials that can circulate through the body and provide diagnostic information or release precisely targeted drugs in response to disease-marker enzymes. Thanks to a newly published paper from researchers at the Advanced Science Research Center (ASRC) at The Graduate Center of The City University of New York, Brooklyn College, and Hunter College, scientists now have design guidance that could rapidly advance development of such nanomaterials.

In the paper, which appears online in the journal ACS Nano, researchers detail broadly applicable findings from their work to characterize a nanomaterial that can predictably, specifically and safely respond when it senses overexpression of the enzyme matrix metalloproteinase-9 (MMP-9). MMP-9 helps the body breakdown unneeded extracellular materials, but when levels are too high, it plays a role in the development of cancer and several other diseases.

“Right now, there are no clear rules on how to optimize the nanomaterials to be responsive to MMP-9 in predictable ways,” said Jiye Son, the study’s lead author and a Graduate Center Ph.D. student working in one of the ASRC Nanoscience Initiative labs. “Our work outlines an approach using short peptides to create enzyme-responsive nanostructures that can be customized to take on specific therapeutic actions, like only targeting tumor cells and turning on drug release in close proximity of these cells.”

Researchers designed a modular peptide that spontaneously assembles into nanostructures, and predictably and reliably morphs or breaks down into amino acids when they come in contact with the MMP-9 enzyme. The designed components include a charged segment of the nanostructure to facilitate its sensing and engagement with the enzyme; a cleavable segment of the structure so that it can lock onto the enzyme and determine how to respond; and a hydrophobic segment of the structure to facilitate self-assembly of the therapeutic response.

“This work is a critical step toward creating new smart-drug delivery vehicles and diagnostic methods with precisely tunable properties that could change the face of disease treatment and management,” said ASRC Nanoscience Initiative Director Rein Ulijn, whose lab is leading the work. “While we specifically focused on creating nanomaterials that could sense and respond to MMP-9, the components of our design guidance can facilitate development of nanomaterials that sense and respond to other cellular stimuli.”

Among other advances, the research team’s work builds on their previous findings, which showed that amino acid peptides can encapsulate and transform into fibrous drug depots upon interaction with MMP-9. The group is collaborating with scientists at Memorial Sloan Kettering and Brooklyn College to use their findings to create a novel cancer therapy.

 Explore further: Scientists create nanomaterials that reconfigure in response to biochemical signals

More information: Jiye Son et al, Customizing Morphology, Size, and Response Kinetics of Matrix Metalloproteinase-Responsive Nanostructures by Systematic Peptide Design, ACS Nano (2019). DOI: 10.1021/acsnano.8b07401

Journal reference: ACS Nano  

Provided by: CUNY Advanced Science Research Center

 

Cornell University: Pore size influences nature of complex nanostructures – Materials for energy storage, biochemical sensors and electronics

The mere presence of void or empty spaces in porous two-dimensional molecules and materials leads to markedly different van der Waals interactions across a range of distances. Credit: Yan Yang and Robert DiStasio

Building at the nanoscale is not like building a house. Scientists often start with two-dimensional molecular layers and combine them to form complex three-dimensional architectures.

And instead of nails and screws, these structures are joined together by the attractive van der Waals forces that exist between objects at the nanoscale.

Van der Waals forces are critical in constructing materials for energy storage, biochemical sensors and electronics, although they are weak when compared to chemical bonds. They also play a crucial role in drug delivery systems, determining which drugs bind to the active sites in proteins.

In new research that could help inform development of new materials, Cornell chemists have found that the empty space (“pores”) present in two-dimensional molecular building blocks fundamentally changes the strength of these van der Waals forces, and can potentially alter the assembly of sophisticated nanostructures.

The findings represent an unexplored avenue toward governing the self-assembly of complex nanostructures from porous two-dimensional building blocks.

“We hope that a more complete understanding of these forces will aid in the discovery and development of novel materials with diverse functionalities, targeted properties, and potentially novel applications,” said Robert A. DiStasio Jr., assistant professor of chemistry in the College of Arts and Sciences.

In a paper titled “Influence of Pore Size on the van der Waals Interaction in Two-Dimensional Molecules and Materials,” published Jan. 14 in Physical Review Letters, DiStasio, graduate student Yan Yang and postdoctoral associate Ka Un Lao describe a series of mathematical models that address the question of how void space fundamentally affects the attractive physical forces which occur over nanoscale distances.

In three prototypical model systems, the researchers found that particular pore sizes lead to unexpected behavior in the physical laws that govern van der Waals forces.

Further, they write, this behavior “can be tuned by varying the relative size and shape of these void spaces … [providing] new insight into the self-assembly and design of complex nanostructures.”

While strong covalent bonds are responsible for the formation of two-dimensional molecular layers, van der Waals interactions provide the main attractive force between the layers. As such, van der Waals forces are largely responsible for the self-assembly of the complex three-dimensional nanostructures that make up many of the advanced materials in use today.

The researchers demonstrated their findings with numerous two-dimensional systems, including covalent organic frameworks, which are endowed with adjustable and potentially very large pores.

“I am surprised that the complicated relationship between void space and van der Waals forces could be rationalized through such simple models,” said Yang. “In the same breath, I am really excited about our findings, as even small changes in the van der Waals forces can markedly impact the properties of molecules and materials.”

Explore further: Researchers refute textbook knowledge in molecular interactions

More information: Yan Yang et al, Influence of Pore Size on the van der Waals Interaction in Two-Dimensional Molecules and Materials, Physical Review Letters (2019).  DOI: 10.1103/PhysRevLett.122.026001 

MIT – Nanoparticles Deliver Potential Arthritis Treatment and could Prevent Cartilage Breakdown – Potential to Heal Tissue Damaged by Osteoarthritis

Six days after treatment with IGF-1 carried by dendrimer nanoparticles (blue), the particles have penetrated through the cartilage of the knee joint. Image: Brett Geiger and Jeff Wyckof

Courtesy of MIT News

Injectable material made of nanoscale particles can deliver arthritis drugs throughout cartilage.

Osteoarthritis, a disease that causes severe joint pain, affects more than 20 million people in the United States. Some drug treatments can help alleviate the pain, but there are no treatments that can reverse or slow the cartilage breakdown associated with the disease.

In an advance that could improve the treatment options available for osteoarthritis, MIT engineers have designed a new material that can administer drugs directly to the cartilage. The material can penetrate deep into the cartilage, delivering drugs that could potentially heal damaged tissue.

“This is a way to get directly to the cells that are experiencing the damage, and introduce different kinds of therapeutics that might change their behavior,” says Paula Hammond, head of MIT’s Department of Chemical Engineering, a member of MIT’s Koch Institute for Integrative Cancer Research, and the senior author of the study.

In a study in rats, the researchers showed that delivering an experimental drug called insulin-like growth factor 1 (IGF-1) with this new material prevented cartilage breakdown much more effectively than injecting the drug into the joint on its own.

Brett Geiger, an MIT graduate student, is the lead author of the paper, which appears in the Nov. 28 issue of Science Translational Medicine. Other authors are Sheryl Wang, an MIT graduate student, Robert Padera, an associate professor of pathology at Brigham and Women’s Hospital, and Alan Grodzinsky, an MIT professor of biological engineering.

Better delivery

Osteoarthritis is a progressive disease that can be caused by a traumatic injury such as tearing a ligament; it can also result from gradual wearing down of cartilage as people age. A smooth connective tissue that protects the joints, cartilage is produced by cells called chondrocytes but is not easily replaced once it is damaged.

Previous studies have shown that IGF-1 can help regenerate cartilage in animals. However, many osteoarthritis drugs that showed promise in animal studies have not performed well in clinical trials.

The MIT team suspected that this was because the drugs were cleared from the joint before they could reach the deep layer of chondrocytes that they were intended to target. To overcome that, they set out to design a material that could penetrate all the way through the cartilage.

The sphere-shaped molecule they came up with contains many branched structures called dendrimers that branch from a central core. The molecule has a positive charge at the tip of each of its branches, which helps it bind to the negatively charged cartilage. Some of those charges can be replaced with a short flexible, water-loving polymer, known as PEG, that can swing around on the surface and partially cover the positive charge. Molecules of IGF-1 are also attached to the surface.

When these particles are injected into a joint, they coat the surface of the cartilage and then begin diffusing through it. This is easier for them to do than it is for free IGF-1 because the spheres’ positive charges allow them to bind to cartilage and prevent them from being washed away. The charged molecules do not adhere permanently, however. Thanks to the flexible PEG chains on the surface that cover and uncover charge as they move, the molecules can briefly detach from cartilage, enabling them to move deeper into the tissue.

“We found an optimal charge range so that the material can both bind the tissue and unbind for further diffusion, and not be so strong that it just gets stuck at the surface,” Geiger says.

Once the particles reach the chondrocytes, the IGF-1 molecules bind to receptors on the cell surfaces and stimulate the cells to start producing proteoglycans, the building blocks of cartilage and other connective tissues. The IGF-1 also promotes cell growth and prevents cell death.

Joint repair

When the researchers injected the particles into the knee joints of rats, they found that the material had a half-life of about four days, which is 10 times longer than IGF-1 injected on its own. The drug concentration in the joints remained high enough to have a therapeutic effect for about 30 days. If this holds true for humans, patients could benefit greatly from joint injections — which can only be given monthly or biweekly — the researchers say.

In the animal studies, the researchers found that cartilage in injured joints treated with the nanoparticle-drug combination was far less damaged than cartilage in untreated joints or joints treated with IGF-1 alone. The joints also showed reductions in joint inflammation and bone spur formation.

“This is an important proof-of-concept that builds on the recent advances in the identification of anabolic growth factors with clinical promise (such as IGF-1), with promising disease-modifying results in a clinically relevant model. Delivery of growth factors using nanoparticles in a manner that sustains and improves treatments for osteoarthritis is a significant step for nanomedicines,” says Kannan Rangaramanujam, a professor of ophthalmology and co-director of the Center for Nanomedicine at Johns Hopkins School of Medicine, who was not involved in the research.

Cartilage in rat joints is about 100 microns thick, but the researchers also showed that their particles could penetrate chunks of cartilage up to 1 millimeter — the thickness of cartilage in a human joint.

“That is a very hard thing to do. Drugs typically will get cleared before they are able to move through much of the cartilage,” Geiger says. “When you start to think about translating this technology from studies in rats to larger animals and someday humans, the ability of this technology to succeed depends on its ability to work in thicker cartilage.”

The researchers began developing this material as a way to treat osteoarthritis that arises after traumatic injury, but they believe it could also be adapted to treat age-related osteoarthritis. They now plan to explore the possibility of delivering different types of drugs, such as other growth factors, drugs that block inflammatory cytokines, and nucleic acids such as DNA and RNA.

The research was funded by the Department of Defense Congressionally Funded Medical Research Program and a National Science Foundation fellowship.

University of Cambridge: Researchers to target hard-to-treat cancers

A £10 million interdisciplinary collaboration is to target the most challenging of cancers using nanomedicine.

“We are going to pierce through the body’s natural barriers and deliver anti-cancer drugs to the heart of the tumour.” – George Malliaras

While the survival rate for most cancers has doubled over the past 40 years, some cancers such as those of the pancreas, brain, lung and oesophagus still have low survival rates.

Such cancers are now the target of an Interdisciplinary Research Collaboration (IRC) led by the University of Cambridge and involving researchers from Imperial College London, University College London and the Universities of Glasgow and Birmingham.

“Some cancers are difficult to remove by surgery and highly invasive, and they are also hard to treat because drugs often cannot reach them at high enough concentration,” explains George Malliaras, Prince Philip Professor of Technology in Cambridge’s Department of Engineering, who leads the IRC. “Pancreatic tumour cells, for instance, are protected by dense stromal tissue, and tumours of the central nervous system by the blood-brain barrier.”

The aim of the project, which is funded for six years by the Engineering and Physical Sciences Research Council, is to develop an array of new delivery technologies that can deliver almost any drug to any tumour in a large enough concentration to kill the cancerous cells.

Chemists, engineers, material scientists and pharmacologists will focus on developing particles, injectable gels and implantable devices to deliver the drugs. Cancer scientists and clinicians from the Cancer Research UK Cambridge Centre and partner sites will devise and carry out clinical trials. Experts in innovative manufacturing technologies will ensure the devices are able to be manufactured and robust enough to withstand surgical manipulation.

One technology the team will examine is the ability of advanced materials to self-assemble and entrap drugs inside metal-organic frameworks. These structures can carry enormous amounts of drugs, and be tuned both to target the tumour and to release the drug at an optimal rate.

“We are going to pierce through the body’s natural barriers,” says Malliaras, “and deliver anti-cancer drugs to the heart of the tumour.”

Dr Su Metcalfe, a member of George Malliaras’s team and who is already using NanoBioMed to treat Multuple Sclerosis, added “the power of nanotechnology to synergise with potent anti-cancer drugs will be profound and the award will speed delivery to patients.”

How nanotechnology is advancing drug delivery

Nanotechnology brings a lot to the medical field, and a specific branch known as nanomedicine has evolved because of the growing interest in this area.

Drug delivery systems derived from materials (or particles) at the nano-level provide a way for drugs, that might otherwise be toxic to the body, to reach their intended target through encapsulation or conjugation approaches.

There are some issues which need to be ironed out, with respect to the size of some of these carriers against the regulatory definitions, but it is an area that is expanding drug delivery approaches beyond what was previously possible with conventional approaches.

Inorganic Nanocarriers

Inorganic nanocarriers were the first type of nanotechnology-based drug delivery system to be trialled, yet their use and research is becoming less and less frequent. Many types of inorganic nanoparticle have been tried and tested, from gold, to iron oxide, to calcium phosphate, and beyond. Many inorganic nanoparticles are not biocompatible within the body, however, this can be overcome by functionalising the surface with organic molecules, such as PEG, to increase their compatibility within the body.

However, where this area has been let down is in their inability to be easily broken down after use and the subsequent difficulty to be excreted.

Organic Nanocarriers

Organic-based nanocarriers are the fastest growing area of nano-inspired drug delivery systems, and the reason for this expansion is due to the (often) inability of inorganic drug carriers to be broken down within the body and excreted. By comparison, the organic make-up of organic carriers, such as those made of certain types of polymers, dendrimer architectures and lipid-based encapsulating vessels (liposomes), can be broken down and excreted and offer a much greater degree of biocompatibility.

Each mechanism of delivery is different for these systems. For example, dendrimer-based delivery vessels will often have the drug covalently linked (conjugated) to the dendrimer backbone itself, and when it reaches a target of interest, certain functional groups at the edges will bind to the target and release the drug through molecular cleavage.

However, the most common way of delivering drugs is through encapsulation, as the toxicity (and the possibility of the drug interacting with the body before it reaches the target) is significantly reduced.

By using this approach, the nanocarrier can uptake the drug of interest into its core, where it is only released once the nanocarrier has reached the target of interest—thus lowering the risk of the drug being cleaved and released on route to the target site.

Solid Drug Nanoparticles

 Solid drug nanoparticles are another growing nanotechnology-inspired drug delivery system, but their use is not (yet) as widespread as organic delivery vessels. However, they do avoid some of the regulatory complications, as their use does not involve any extra species other than already approved drugs in an efficient nanoparticle form.

Solid drug nanoparticles are the nanoparticle form of a conventional drug; and take the form of being packed into a template, or as a suspension—therefore no delivery system is required and are administered by injection. The drug nanoparticles are often created through a bottom-up controlled precipitation of the drug to be administered, or by a top-down grinding approach of larger pieces of the drug until they are in the nanoparticle size range.

Aside from providing a more straightforward route to the clinic from a regulatory perspective, they also offer a way to tackle drug adherence issues—i.e. where people don’t take their required medication on time, which causes the effectiveness of the drug to be reduced—by providing a long-lasting, slow release of the drug over a period of 1 to 6 months.

Contributed and Written by Liam Critchley

Nano Magazine the magazine for Small Science

Identifying the ‘Culprit’ (molecule) for the Cause of Alzheimer’s: A ‘Big Bang’ Research Breakthrough at UT Southwestern O’Donnell Brain Institute + Video

It’s being called the “big bang” breakthrough in Alzheimer’s research. Doctors at UT Southwestern’s O’Donnell Brain Institute have detected what they believe are changes in a single molecule that could act as the starting point for the deadly, memory-stealing disease.

Scientists are fairly certain that a molecule called “tau” is the culprit.

Alzheimer’s is characterized by clumps of tangled protein in the brain. According to the Alzheimer’s Association, one in three seniors will die of the disease — and that’s more than breast and prostate cancer combined.

Ultimately, researchers hope that warning signals for the disease can be effectively detected and therefore prevented with something as simple as a vaccine or pill.

“I anticipate a day when we will think about these diseases like Alzheimer’s and Parkinson’s as problems that only people who don’t get medical care develop,” said Dr. Diamond.

Researchers know that there is much work ahead. It could be several years before the discovery is ready for human clinical trials. Until then, supporters say it’s critical for lawmakers to fund research at all levels.

Patients can also get involved in local studies so doctors can learn as much as they can from seniors as they age. And while the advances won’t happen overnight, doctors say the overriding message for the community in the discovery is that there is hope.

“There’s tremendous hope!” said Dr. Diamond. “We are actually super excited in our field. When I look at the future, I see many, many opportunities for good shots on goal.”

And if he’s right, the discovery could be a life-changing win for the world.

Watch the Video

 

Penn State: Camouflaged nanoparticles deliver killer ‘knock-out’ protein to cancer

Extracellular vesicle-like metal-organic framework nanoparticles are developed for the intracellular delivery of biofunctional proteins. The biomimetic nanoplatform can protect the protein cargo and overcome various biological barriers to achieve systemic delivery and autonomous release. Credit: Zheng Lab/Penn State

 

A biomimetic nanosystem can deliver therapeutic proteins to selectively target cancerous tumors, according to a team of Penn State researchers.

A biomimetic nanosystem can deliver therapeutic proteins to selectively target cancerous tumors, according to a team of Penn State researchers. Using a protein toxin called gelonin from a plant found in the Himalayan mountains, the researchers caged the proteins in self-assembled metal-organic framework (MOF) nanoparticles to protect them from the body’s immune system. To enhance the longevity of the drug in the bloodstream and to selectively target the tumor, the team cloaked the MOF in a coating made from cells from the tumor itself.

Blood is a hostile environment for drug delivery. The body’s immune system attacks alien molecules or else flushes them out of the body through the spleen or liver. But cells, including cancer cells, release small particles called extracellular vesicles that communicate with other cells in the body and send a “don’t eat me” signal to the immune system.

“We designed a strategy to take advantage of the extracellular vesicles derived from tumor cells,” said Siyang Zheng, associate professor of biomedical and electrical engineering at Penn State. “We remove 99 percent of the contents of these extracellular vesicles and then use the membrane to wrap our metal-organic framework nanoparticles. If we can get our extracellular vesicles from the patient, through biopsy or surgery, then the nanoparticles will seek out the tumor through a process called homotypic targeting.”

Gong Cheng, lead author on a new paper describing the team’s work and a former post-doctoral scholar in Zheng’s group now at Harvard, said, “MOF is a class of crystalline materials assembled by metal nodes and organic linkers. In our design, self-assembly of MOF nanoparticles and encapsulation of proteins are achieved simultaneously through a one-pot approach in aqueous environment. The enriched metal affinity sites on MOF surfaces act like the buttonhook, so the extracellular vesicle membrane can be easily buckled on the MOF nanoparticles. Our biomimetic strategy makes the synthetic nanoparticles look like extracellular vesicles, but they have the desired cargo inside.”

The nanoparticle system circulates in the bloodstream until it finds the tumor and locks on to the cell membrane. The cancer cell ingests the nanoparticle in a process called endocytosis. Once inside the cell, the higher acidity of the cancer cell’s intracellular transport vesicles causes the metal-organic framework nanoparticles to break apart and release the toxic protein into cytosol and kill the cell.

“Our metal-organic framework has very high loading capacity, so we don’t need to use a lot of the particles and that keeps the general toxicity low,” Zheng said.

The researchers studied the effectiveness of the nanosystem and its toxicity in a small animal model and reported their findings in a cover article in the Journal of the American Chemical Society.

The researchers believe their nanosystem provides a tool for the targeted delivery of other proteins that require cloaking from the immune system. Penn State has applied for patent protection for the technology.

---

Story Source:

Materials provided by Penn State. Original written by Walt Mills. Note: Content may be edited for style and length.

 

New Simple Blood Test can Detect Alzheimer’s 30 Years in Advance + Can Also Detect 8 Cancers: Videos

New Simple Blood Test can Detect Alzheimer’s 30 Years in Advance + Can Also Detect 8 Cancers

#GreatThingsFromSmallThings

Watch the Videos Below

Detecting Alzheimer’s 30 Years in Advance

8 Cancers Detected with ONE Simple Blood Test

The remarkable nanostructure of human bone – Revealed

Interweaving mineral and protein form continuous networks to provide the strength essential for functional bones.

Credit: Dr Roland Kröger

Summary:

Using advanced 3D nanoscale imaging of the mineral in human bone, research teams have shown that the mineral crystals of bone have a hierarchical structure integrated into the larger-scale make-up of the skeleton.

Scientists have produced a 3D nanoscale reconstruction of the mineral structure of bone.

Bone performs equally well whether in an accelerating cheetah or in a heavy elephant, thanks to its toughness and strength.

The properties of bone can be attributed to its hierarchical organisation, where small elements form larger structures.

However, the nanoscale organisation and relationship between bone’s principle components — mineral and protein — have not been fully understood.

Using advanced 3D nanoscale imaging of the mineral in human bone, research teams from the University of York and Imperial College London have shown that the mineral crystals of bone have a hierarchical structure integrated into the larger-scale make-up of the skeleton.

Researchers combined a number of advanced electron microscopy-based techniques, and found that the principal building blocks of mineral at the nanometre scale are curved needle-shaped nanocrystals that form larger twisted platelets that resemble propeller blades.

The blades continuously merge and split throughout the protein phase of bone. The interweaving mineral and protein form continuous networks to provide the strength essential for functional bones.

Lead author, Associate Professor Roland Kröger, from the University of York’s Department of Physics, said: “Bone is an intriguing composite of essentially two materials, the flexible protein collagen and the hard mineral called apatite.”

“There is a lot of discussion about the way these two stiff and flexible phases uniquely combine to provide toughness and strength to bone.

“The combination of the two materials in a hierarchical manner provides bone with mechanical properties that are superior to those of its individual components alone and we find that there are 12 levels of hierarchy in bone.”

Dr Natalie Reznikov, formerly of Imperial College, London and an author on the paper, said: “If we compare this arrangement, for example, to an individual living in a room of a house, this extends to a house in a street, then the street in a neighbourhood, a neighbourhood in a city, a country and on it goes. If you continue to 12 levels you are reaching the size of a galaxy! ”

Professor Molly Stevens, from Imperial College, London, added: “This work builds on the shoulders of many beautiful previous studies investigating the fundamental properties and structure of bone and helps to unlock an important missing piece of the puzzle.”

Besides the large number of nested structures in bone, a common feature of all of them is a slight curvature, providing twisted geometry. To name a few, the mineral crystals are curved, the protein strands (collagen) are braided, the mineralized collagen fibrils twist, and the entire bones themselves have a twist, such as those seen in the curving shape of a rib for example.

Fractals are common in Nature: you can see self-similar patterns in lightning bolts, coast lines, tree branches, clouds and snowflakes. This means that the structure of bone follows a fundamental order principle in Nature.

The authors believe that the fractal-like structure of bone is one of the key reasons for its remarkable attributes.

The findings are published in the journal Science.

NanoSphere Health Sciences Awarded Breakthrough Patent for Disruptive Nanoparticle Delivery Platform

Landmark patent marks most significant advancement in over 25 years for non-invasive medical delivery systems

Photo Credit: NanoSphere Health Sciences

DENVER, CO – APRIL 2018 – NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.

The research-proven NanoSphere Delivery System™, protected by this patent, is one of the most important advancements for the non-invasive delivery of biological agents in over 25 years. The patent broadly encompasses the formation and manufacturing of the NanoSphere Delivery System™ for the delivery of cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals and other biological agents.

NanoSphere’s groundbreaking NanoSphere Delivery System™ nanoencapsulates a broad range of bioactive compounds in a protective membrane, transporting them rapidly and effectively to the bloodstream and cells for greater efficacy. This delivery platform is a breakthrough in pharmaceutical, cannabinoid, nutraceutical and cosmeceutical supplement delivery. It makes the nanoencapsulated agents safer and more bioavailable, reducing adverse effects by delivering precise doses of smart nanoparticles to target sites.

“The granting of the patent for the NanoSphere Delivery System™ secures our position as a leader in advanced nanoparticle delivery,” said Robert Sutton, CEO of NanoSphere Health Sciences. “Major industries have the potential to be reshaped and reimagined by our next-generation technology.”

“NanoSphere’s patent claims and protects our core technology for the formation and manufacturing of lipid, structural nanoparticles, which is the NanoSphere Delivery System™,” said Dr. Richard Clark Kaufman, Chief Science Officer and inventor of the NanoSphere Delivery System™. “This patent extends to our 16 forms of lipid nanoparticle structures, which can be applied across healthcare sectors for vastly improved medical delivery.”

With the issuance of this patent, the NanoSphere will now have long-term market exclusivity over this delivery platform, with patent infringement prohibited. The company intends to license the patented NanoSphere Delivery System™ and proprietary manufacturing process to selected companies in its target industries to maximize commercialization. This patent allows NanoSphere to bring to the world the NanoSphere Delivery System™ through multiple product lines and platforms, such as the company’s cannabis brand Evolve Formulas’ transdermal, intranasal and intraoral applications and beyond.

SOURCE NanoSphere Health Sciences INC

 

About NanoSphere

NanoSphere Health Sciences LLC, a subsidiary of NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), is the leader in nanoparticle delivery, a biotechnology company advancing the NanoSphere Delivery System™.  NanoSphere’s patented core technology is changing the way biological agents deliver benefits.

NanoSphere’s disruptive platforms use smart nanoparticles to deliver cannabinoids, nutraceuticals, pharmaceuticals and over-the-counter medications in a patented process with greater bioavailability and efficacy for the cannabis, nutraceutical, pharmaceutical, cosmeceutical and animal health industries.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.